AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures and sells pharmaceuticals worldwide. It is set to report the Q4 ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

AbbVie and Neomorph are set to enter a partnership and option-to-license agreement to develop molecular glue degraders.

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

The National Medical Commission has launched an investigation into doctors whose foreign trips, funded by AbbVie Healthcare, ...

Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced ...

The National Medical Commission (NMC) has started its probe against 30 doctors who allegedly took pharma freebies in the form ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of ...

Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today ...

AbbVie is one of the better pharmaceutical stocks on the scene, buttressed by a strong product lineup and a promising pipeline of developmental programs. It also pays quite a generous dividend ...